Journey Medical Q3 revenue up 21% on increase in Emrosi prescriptions

Journey Medical

12/11/2025 21:09

Overview

Journey Medical Q3 2025 revenue grows 21% yr/yr but misses analyst expectations

Emrosi prescriptions rose 146% over Q2 2025, boosting Q3 net revenues to $4.9 mln

Net loss for Q3 2025 slightly improves to $2.3 mln from $2.4 mln in Q3 2024

Outlook

Company expects Emrosi to drive significant operating leverage going forward

Result Drivers

EMROSI PRESCRIPTIONS - Emrosi prescriptions increased 146% over Q2 2025, driving net revenues to $4.9 mln

GROSS MARGIN IMPROVEMENT - Gross margin improved to 67.4% in Q3 2025, driven by higher-margin products and lower inventory costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$17.60 mln
$18.70 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Journey Medical Corp is $12.50, about 27.6% above its November 11 closing price of $9.05

The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNX8Ckf82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)